VRPX (Virpax Pharmaceuticals) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2024)


What is Virpax Pharmaceuticals ROE % Adjusted to Book Value?

Virpax Pharmaceuticals VRPX ROE % Adjusted to Book Value is 0.00% as of Dec. 2024.

Virpax Pharmaceuticals's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Virpax Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Virpax Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.

Virpax Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Virpax Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Virpax Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virpax Pharmaceuticals ROE % Adjusted to Book Value Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 -67.11 -182.02 -84.59 0.00

Virpax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.90 0.00 0.00 0.00 0.00

VRPX vs SYGGF, SCPX, LADX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Virpax Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virpax Pharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Virpax Pharmaceuticals ROE % Adjusted to Book Value Calculation

Virpax Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2,366.08% / N/A
=N/A

Virpax Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Virpax Pharmaceuticals (VRPX) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Virpax Pharmaceuticals and its competitors.
Is Virpax Pharmaceuticals' ROE % Adjusted to Book Value too high?
Virpax Pharmaceuticals' current ROE % Adjusted to Book Value is 0.00%.
How does Virpax Pharmaceuticals' ROE % Adjusted to Book Value compare to SYGGF and SCPX?
Virpax Pharmaceuticals' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Virpax Pharmaceuticals and its competitors. Virpax Pharmaceuticals's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virpax Pharmaceuticals stock overvalued right now?
Virpax Pharmaceuticals (VRPX) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Virpax Pharmaceuticals (VRPX), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Virpax Pharmaceuticals Business Description

Address 1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.